Livtencity (maribavir)

pCPA File Number: 22070
Negotiation Status:
Concluded with an LOI
Indication(s):
Post-transplant Cytomegalovirus (CMV) Infection/disease
Sponsor/Manufacturer:
Takeda Canada Inc.
CDA-AMC Project Number:
SR0720-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: